Landy J and Hart AL |
Commentary: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23336680
|
Hirai F et al. |
Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23336690
|
Schmidt KJ et al. |
Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - authors' reply. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23336691
|
Baumgart DC et al. |
Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12755840
|
BenÃtez C et al. |
Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. Authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28589580
|
Yamamoto T et al. |
Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:26762838
|
Travis S |
Review article: saving the colon in severe colitis - the case for medical therapy. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16961749
|
Schmidt KJ et al. |
Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23121200
|
McSharry K et al. |
Systematic review: the role of tacrolimus in the management of Crohn's disease. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21999607
|
Itoh S et al. |
Inhibition of CN (protein phosphatase-2B) suppresses Ca2+-mediated acid secretion in rats. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966520
|
Yamamoto S et al. |
Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18549460
|
O'Leary JG |
Editorial: tacrolimus-how low can you go? |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28589579
|
Herrlinger KR et al. |
Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20175769
|
Schwrer H et al. |
Pantoprazole and cyclosporine or tacrolimus. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11284790
|
Högenauer C et al. |
Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12940927
|
Yamamoto T et al. |
Letter: which patient profile for tacrolimus in ulcerative colitis? Authors' reply. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27137731
|
Laharie D and Poullenot F |
Letter: which patient profile for tacrolimus in ulcerative colitis? |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27137730
|
Mehta SJ et al. |
Review article: strategies for the management of chronic unremitting ulcerative colitis. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23718288
|
Haagsma EB et al. |
Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12848624
|
Nakase H et al. |
Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus. |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20636704
|